Our Custom Rx Safety Information

Compound: Minoxidil 5% / Finasteride 0.3% / Latanoprost 0.03% / Ketoconazole 2% Hair Spray - 30 mL
Dosage Form: Topical spray (compounded - not FDA-approved)
Typical Use: Prescriber-directed topical therapy for androgenic alopecia / hair loss.
Usual Directions (example): Apply as directed by prescriber to affected scalp area, usually once daily.

Key Components & Risks
- Minoxidil 5%: Topical vasodilator; may cause local irritation, hypertrichosis; rare systemic absorption leading to
hypotension or tachycardia.
- Finasteride 0.3%: 5-alpha-reductase inhibitor; systemic absorption risk of sexual adverse effects (decreased libido,
erectile dysfunction); teratogenic risk if handled by pregnant women.
- Latanoprost 0.03%: Prostaglandin analog; local irritation possible; may cause increased pigmentation of hair/skin;
systemic effects are rare.
- Ketoconazole 2%: Antifungal with anti-androgenic properties; local irritation/burning possible.

Contraindications
- Hypersensitivity to any component of the formulation.
- Pregnancy and breastfeeding: avoid due to finasteride teratogenicity and lack of safety data for others.
- Children: not established safety/efficacy.

Warnings & Precautions
- Avoid ocular exposure (especially with latanoprost).
- Risk of systemic absorption: although minimal, counsel patients on potential side effects (especially with
finasteride/minoxidil).
- Women of childbearing potential: should not handle finasteride-containing formulations.
- Apply only to scalp; avoid broken or irritated skin.
Drug/Skincare Interactions
- Other topical irritants may increase risk of local dermatitis.
- Systemic finasteride or other 5-alpha-reductase inhibitors: additive risk of adverse effects.
- Use caution with antihypertensives (systemic minoxidil absorption could rarely potentiate hypotension).

Adverse Effects (Selected)
- Local: itching, erythema, dryness, burning at site of application.
- Minoxidil: rare systemic hypotension, tachycardia, edema.
- Finasteride: systemic absorption risk of sexual dysfunction, mood changes (rare with topical).
- Latanoprost: hyperpigmentation of hair/skin, mild ocular-type irritation if misapplied.
- Ketoconazole: contact dermatitis, irritation.

Monitoring (Per Prescriber)
- Clinical response: hair density/quality over 3–6 months.
- Monitor for local irritation and discontinue if severe.
- Consider monitoring blood pressure if large areas or excessive amounts are applied.
- Assess for systemic adverse effects (finasteride-related sexual effects, mood).

Patient Counseling Points
- Apply as directed to scalp only; avoid eyes, mouth, and broken skin.
- Wash hands after application; allow product to dry before lying down or wearing hats.
- Women who are pregnant or may become pregnant should not handle this medication.
- Use consistently for at least 3–6 months to assess benefit.
- Report chest pain, dizziness, swelling, unexpected hair/skin pigmentation, or sexual side effects.

Storage & Handling
- Store at controlled room temperature (20–25 C / 68–77 F).
- Protect from heat, flame, and light (alcohol-containing sprays are flammable).
- Keep tightly closed and out of reach of children/pets.

References (Selected)
- DailyMed: Minoxidil topical solution labeling.
- Finasteride oral labeling (DailyMed) – class warnings apply.
- Latanoprost ophthalmic labeling (DailyMed) – extrapolated for topical absorption risks.
- Ketoconazole topical labeling (DailyMed).
- Clinical studies on compounded topical finasteride/minoxidil combinations for androgenic alopecia. 

Disclaimer: For clinical reference by licensed professionals. Not a substitute for prescriber judgment or official
labeling.